Biolegend, 645702, Purified anti-p53 Antibody, 100μg

p53 is a 53 kD protein that forms tetramers and functions as a tumor suppressor and transcriptional activator of genes that inhibit growth and/or invasion, cell cycle checkpoint after irradiation, DNA repair, apoptotic induction, signal transduction, and cell adhesion. This protein is localized to the nucleus when activated and can be upregulated by genotoxic or other cellular stresses. p53 is modified by phosphorylation, acetylation, ribosylation, ubiquitination, and sumoylation; ubiquination targets p53 for degradation via mdm2. This protein interacts with a variety of proteins including mdm2, mdmx, topoisomerase I, PML3, Bcl-X L , Bcl-2, Chk1, JNK, p38, HIPK2, CK2, DNA-PK, p300/CBP, PCAF, PARP1, and HDAC1-3. Mutant p53 associates with p63 and p73.
100μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: P53 N-terminal linear epitope aa 20-25
Formulation: This antibody is provided in phosphate-buffered solution containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: WB - Quality tested ICC, ChIP - Verified IP - Reported in the literature, not verified in house
Recommended Usage: Each lot of this antibody is quality control tested by Western blotting. Western blotting, suggested working dilution(s): Use 0.5 - 1 µg per ml antibody for each mini-gel. For immunocytochemistry, a concentration range of 2.0 - 5.0 μg/ml (Dilution 1:100 - 1:250) is recommended. For ChIP applications, the recommended starting antibody to chromatin ratio is 1 µg of antibody and 5 µg of chromatin per IP. Optimal antibody to chromatin ratio should be determined by the end user. It is recommended that the reagent be titrated for optimal performance for each application.
Application References(PubMed link indicates BioLegend citation): Vojtesek B, et al. 1992. J Immuno Methods 151:237 Stephen CW, et al. 1995. J Mol Biol 248:58
Product Citations: Piccini I, et al. 2022. Br J Dermatol. 186:129. PubMed Geisinger JM, et al. 2020. Nucleic Acids Res. 48:9067. PubMed Linetsky M, et al. 2020. Free Radic Biol Med. 152:280. PubMed Lim J, et al. 2021. Curr Protoc. 1:e29. PubMed
RRID: AB_1595606 (BioLegend Cat. No. 645701) AB_2206462 (BioLegend Cat. No. 645702)
Structure: Tetramer; 53 kD
Distribution: Nuclear when activated
Function: Tumor suppressor, transcription factor regulates cell cycle checkpoint, apoptosis, DNA integrity
Interaction: mdm2, mdmx, TopoI, PML3, Bcl-XL, Bcl-2, Chk1, JNK, p38, HIPK2, CK2, DNA-PK, p300/CBP, PCAF, PARP1, HDAC1-3; mutant p53 associates with p63, p73
Cell Type: Mesenchymal Stem Cells
Biology Area: Cell Biology, DNA Repair/Replication, Stem Cells, Transcription Factors
Antigen References: 1. Vogelstein B, et al. 1992. Cell. 70:523. 2. Shieh S, et al. 1997. Cell. 91:325. 3. Mihara M, et al. 2003. Mol. Cell 11:577. 4. Saito S, et al. 2003. J. Biol. Chem. 278:37536.
Gene ID: 7157
UniProt: View information about p53 on UniProt.org
Clone: DO-1
Regulatory Status: RUO
Other Names: Tumor protein p53 (TP53)
Isotype: Mouse IgG2a, κ